Abstracts non-medical costs (i.e., physician visits, hospitalizations, and special nurses/caregivers) were retrieved from a private hospital in Thailand. Effectiveness was defined as the improvement of the Alzheimer's disease assessment scale-cognitive subscale (ADAS-cog) scores. Effectiveness data and probabilities used in the model were obtained from relevant published studies. Sensitivity analyses were performed to determine the model robustness. RESULTS: The cost-effectiveness analyses shows that compared with no treatment, incremental cost of high doserivastigmine costs the lowest for patients with Alzheimer's Disease to gain one point improvement of ADAS-cog score [30,162 Baht ($754) per year], whereas the incremental cost of donepezil was 32,362 ($809) Baht per year and low doserivastigmine costs the highest [77,102 ($1928 4 AstraZeneca LP, Wilmington, DE, USA OBJECTIVE: Quetiapine has been shown to be effective in the treatment of behavioral and psychological signs of dementia (BPSD). This analysis evaluates the cost-effectiveness of treating community-dwelling patients with Alzheimer's disease (AD) and BPSD in the US. METHODS: A discrete event simulation was designed to track the symptoms of BPSD and the resulting influence on costs, caregiver burden and institutionalization in individuals under two scenarios: treatment with quetiapine at 200 mg per day, and no treatment. The model is populated using data from a randomized trial comparing quetiapine to placebo, a longitudinal cohort study in AD patients, US costing sources, and the literature. Costs, reported in 2004 US dollars, are examined from the perspective of a comprehensive health care payer and society, and include doctor visits, nursing home stays, hospitalization, adult day care, home health care, caregiver time and quetiapine treatment. In the base case, a one year time horizon is used. RESULTS: On average, untreated patients spend just over 60% of their time in the community with high levels of BPSD, while caregivers spend an average of 5.7 hours per day caring for patients. Per patient costs average $35,642, 77% of which consists of informal caregiving costs. Quetiapine reduces the time spent with high BPSD by 24 days, while caregiver time is reduced by 76 hours per patient. A modest reduction in institutionalization (9%) is also predicted. The net effect is an increase in direct costs of $439 per patient ($6830 per high BPSD year avoided), but savings of $738 from the societal perspective. A total of 96% of replications resulted in quetiapine dominating no treatment from the societal perspective. Results are particularly sensitive to caregiver time valuation. CONCLUSIONS: Treatment with quetiapine has the potential to alleviate caregiver burden and can lead to considerable savings from the societal perspective.
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PNL4 NURSING HOME RESIDENTS WITH ALZHEIMER'S DISEASE: CHANGES IN MANAGEMENT LEVELS AND COSTS OVER A SIX YEAR PERIOD
O'Brien J, Duran P, Caro JJ Caro Research Institute, Concord, MA, USA OBJECTIVES: To identify changes in management levels and costs for a cohort of nursing home residents admitted for Alzheimer's disease (AD) over a six-year period. METHODS: Long-term care data from Minnesota for 1995 through 2000 were examined. Nurses from Minnesota's Quality Assurance and Review Program evaluate care needs of nursing home residents annually. Residents are classified according to dependence level in each of eight activities of daily living (ADL). This ADL assessment and other factors establish the management level and reimbursement rate for care. AD cases were identified using ICD-9 principal diagnosis codes and personal identifiers. Only patients with AD who were residents throughout the six years were analyzed. Nursing home reimbursement rates for 2002 were obtained from Minnesota's Department of Human Services. Cost estimates include nursing and ancillary staff care, and room and board. Costs are reported in 2002 US$. RESULTS: Of the 2382 assessed patients with AD identified in 1995, 382 qualified for this analysis. Of those, 90% were female and the mean age was 81 years (range: 56-101). Behavior problems were noted in 71% in 1995 and 2000. In 1995, 25% received an antipsychotic agent regularly. This rate decreased each year and was 15% by 2000. The proportion of residents in low and medium dependency levels decreased from 59% to 16% over six years; whereas, the high dependency group rose from 41% to 84%. In 2000, significantly (p = 0.000) more residents were assessed as physically and mentally incapable of self-preservation than in 1995. On average, this increase in care needs resulted in an additional annual cost of $7273 per resident by the end of the six-year period and roughly $2.6 million for the cohort. CONCLU-SIONS: Patients with AD residing in nursing homes continue to deteriorate over time, resulting in a substantial increase in care needs and costs. Patients who refilled their initial ChEI prescription within a permissible gap of 60 days after depleting the drug supply from the prior prescription were considered to be persistent and the robustness of the persistency definition was tested using sensitivity analysis. Kaplan-Meier method and Cox proportional hazard models were performed to examine the trends of persistency and to identify factors that significantly influenced persistency. RESULTS: During the 1-year follow-up period, 53% of rivastigmine and donepezil users discontinued or switched their medications. Discontinuation was more common in donepezilusers (43%) than in rivastigmine-users (37%), but switching occurred more frequently in rivastigmine users (16% vs. 10%). Rivastigmine-users continuously used their medication for an average of 234 days while donepezil-users for 235 days (p = 0.91). Results were stable with variations in the definition of con-tinuous therapy. The risk of discontinuation/switching was not statistically different between the two groups. Patients who used a CNS medication before initiation of therapy, did not visit their physician office frequently or were not hospitalized after initiation of ChEI therapy were more likely to discontinue/switch their initial ChEI. CONCLUSION: Levels of persistency among the elderly patients with AD is similar between rivastigmine and donepezil in a real-world setting. Further research is needed to determine ways of improving persistency and to estimate the long-term economic impact of persistency with ChEIs on AD treatment costs. were retrieved from a 20% sample of the California Medicaid (Medi-Cal) claims database. The index date for the antidepressant group was defined as the dispensing date of first antidepressant medication, and for the control group, it was defined as the date of initial AD diagnosis. Generalized linear models (GLM) with log link function and gamma distribution were applied to compare the first year total post-index medical (nonpharmacy) costs and the total health care costs between the groups, controlling for demographics, comorbidities, and prior utilization. Cox proportional hazard regression was used to model the time to first LTC admission since index date, adjusting for the same set of covariates. RESULTS: In total, 3515 AD patients were identified, with 1645 in the antidepressant group and 1870 in the control. AD patients with antidepressants were younger (77 vs. 80 years, p < 0.0001), had higher proportion of Caucasians (57% vs. 53%, p < 0.0001), and had a similar comorbidity profile as the control group. Adjusted for potential confounders, the GLM estimates showed that using antidepressants was related to 40% and 36% lower post-index total medical costs and total health care costs (p < 0.0001 for both), respectively. In the Cox regression, antidepressant group had 34% lower risk of admission to LTC than the control group (P < 0.0001). CONCLUSIONS: In this study, antidepressant use in AD patients associated a significant reduction in total costs and appeared to postpone long-term care admission.
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PNL6 OUTCOMES OF ANTIDEPRESSANT USE IN PATIENTS WITH ALZHEIMER'S DISEASE IN THE
PNL7 DIAGNOSING PHYSICIANS, PRESCRIPTION CHOICE AND PATTERNS FOR ALZHEIMER'S DISEASE IN CALIFORNIA MEDICAID PROGRAM
Yu AP 1 , Lee LJ 1 ,Yu YF 2 , Nichol MB 3 1 University of Southern California, Los Angeles, CA, USA; 2 HealthCore, Inc, Wilmington, DE, USA; 3 University of Southern California, School of Pharmacy, Los Angeles, CA, USA OBJECTIVES: Although acetylcholinesterase inhibitors (AChEI) are the only class of drugs indicated for Alzheimer's disease (AD), drugs treating non-cognitive symptoms and drugs possibly beneficial to cognitive functions (e.g. estrogen, selegiline) are also prescribed for AD patients in practice. This study investigated 1) Characteristics of physicians giving the initial AD diagnosis; 2) prescription choice and patterns for AD in a Medicaid population. METHODS: AD Patients with a minimum of 12 months continuous eligibility after initial diagnosis of AD were identified from a 20% Medi-Cal claims database of 1995-2002. During the first year follow-up, the prescription claims of the following drug classes were analyzed: AChEI, antidepressants, antianxiety agents, antipsychotics, estrogen and antiparkinsonian MAO inhibitor (e.g. selegiline). Regression models were applied to study the prescription pattern. RESULTS: A total of 4386 AD patients were initially diagnosed by 2205 unique physicians. Among 1055 AD patients diagnosed by physicians with specialty information, 35.5% were diagnosed by primary care physicians (PCPs), 22.6% by internists, 19.4% by neurologists, 4.3% by psychiatrist, and the rest by other specialists. During the first year of follow up, 42.5% patients did not receive any AD-related medications. Controlling for demographics, diagnosis year and comorbidities, patients diagnosed by PCPs were least likely to get any prescription compared to neurologists (OR = 1.64, p = 0.01), and psychiatrists (OR = 2.22, p = 0.0065). Antipsychotics were the most frequently prescribed drugs (34.0% patients), followed by antidepressants (27.2%), and antianxiety agents (16.1% The feasibility and accuracy of obtaining patient reported outcomes electronically, particularly from elderly subjects, has been questioned. OBJECTIVE: To pilot the use of a telephone-based Interactive Voice Response Data Entry System (IVRS) by elderly caregivers of patients with Alzheimer's Disease. METHODS: Caregivers were trained by nurses to record patient and caregiver health care utilization data into a 30-day diary and to enter these data using IVRS. The system was accessed via a toll-free telephone number using a unique subject identifier. Caregivers had 15 minutes to read detailed training notes in the waiting room. Feasibility and accuracy parameters assessed were time to train, time to enter the data and accuracy of hypothetical diary data entry. RESULTS: Time to train the caregiver (60% women, 52 to 80+ years old) on both the use of the diary and IVRS data entry ranged from 36 to 48 minutes. Thirty days of hypothetical diary data provided to the patient for the exercise were entered via IVRS in 8 to 12 minutes per subject. No significant difficulties were observed with any caregiver and only one data point by one caregiver was incorrectly entered. IVRS features such as question repeat, invalid answer prompt, and automatic re-entry to last question answered if entry was interrupted all worked well. Caregivers expressed their willingness to use the diary daily and to enter data every 30 days over the planned 18-
